Analysts predict that EXACT Sciences Co. (NASDAQ:EXAS) will announce earnings per share of ($0.42) for the current quarter, Zacks reports. Five analysts have made estimates for EXACT Sciences’ earnings, with the highest EPS estimate coming in at ($0.34) and the lowest estimate coming in at ($0.46). EXACT Sciences reported earnings per share of ($0.23) during the same quarter last year, which would suggest a negative year-over-year growth rate of 82.6%. The business is expected to report its next earnings report on Monday, October 29th.

According to Zacks, analysts expect that EXACT Sciences will report full-year earnings of ($1.41) per share for the current year, with EPS estimates ranging from ($1.52) to ($1.32). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.82) per share, with EPS estimates ranging from ($1.20) to ($0.35). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for EXACT Sciences.

EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Wednesday, August 1st. The medical research company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.03. EXACT Sciences had a negative return on equity of 20.10% and a negative net margin of 35.24%. The business had revenue of $102.89 million during the quarter, compared to analyst estimates of $104.40 million. During the same period in the prior year, the company earned ($0.27) earnings per share. EXACT Sciences’s revenue was up 78.5% compared to the same quarter last year.

EXAS has been the subject of several research reports. Leerink Swann reissued an “outperform” rating and set a $76.00 price objective (up from $67.00) on shares of EXACT Sciences in a report on Wednesday, July 18th. BTIG Research reissued a “buy” rating on shares of EXACT Sciences in a report on Tuesday, June 5th. Canaccord Genuity increased their price objective on EXACT Sciences from $72.00 to $87.00 and gave the company a “buy” rating in a report on Wednesday, September 12th. BidaskClub lowered EXACT Sciences from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 26th. Finally, Zacks Investment Research raised EXACT Sciences from a “sell” rating to a “hold” rating in a report on Monday, June 4th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $81.73.

Shares of NASDAQ EXAS opened at $76.28 on Thursday. EXACT Sciences has a 1-year low of $37.36 and a 1-year high of $80.35. The company has a debt-to-equity ratio of 0.87, a quick ratio of 15.37 and a current ratio of 15.79.

In other news, Director Thomas D. Carey sold 3,427 shares of the firm’s stock in a transaction on Monday, July 30th. The stock was sold at an average price of $58.86, for a total value of $201,713.22. Following the completion of the transaction, the director now directly owns 48,983 shares of the company’s stock, valued at $2,883,139.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael S. Wyzga sold 2,468 shares of the firm’s stock in a transaction on Tuesday, August 28th. The stock was sold at an average price of $74.85, for a total value of $184,729.80. Following the completion of the transaction, the director now directly owns 9,112 shares of the company’s stock, valued at $682,033.20. The disclosure for this sale can be found here. Insiders sold 17,014 shares of company stock valued at $1,031,717 over the last ninety days. Corporate insiders own 3.20% of the company’s stock.

Several institutional investors have recently bought and sold shares of EXAS. Asymmetry Capital Management L.P. boosted its stake in EXACT Sciences by 229.2% during the second quarter. Asymmetry Capital Management L.P. now owns 84,937 shares of the medical research company’s stock valued at $5,078,000 after buying an additional 59,134 shares during the period. Swiss National Bank boosted its stake in EXACT Sciences by 1.4% during the second quarter. Swiss National Bank now owns 210,619 shares of the medical research company’s stock valued at $12,593,000 after buying an additional 3,000 shares during the period. Sit Investment Associates Inc. boosted its stake in EXACT Sciences by 24.3% during the second quarter. Sit Investment Associates Inc. now owns 33,300 shares of the medical research company’s stock valued at $1,991,000 after buying an additional 6,500 shares during the period. Hartford Investment Management Co. bought a new stake in EXACT Sciences during the second quarter valued at $202,000. Finally, Formula Growth Ltd. boosted its stake in EXACT Sciences by 30.8% during the second quarter. Formula Growth Ltd. now owns 42,500 shares of the medical research company’s stock valued at $2,541,000 after buying an additional 10,000 shares during the period. 86.40% of the stock is owned by hedge funds and other institutional investors.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Read More: NASDAQ

Get a free copy of the Zacks research report on EXACT Sciences (EXAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.